Todd W. Markowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Todd W. Markowski has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Adam Sheka
Univ Minnesota Twin Cities, Dept Surg, Minneapolis, MN USA
19 shared publications - Ann V. Hertzel
Masonic Institute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, USA
19 shared publications - David A. Bernlohr
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA
19 shared publications - Dongmei Chen
Departments of Biochemistry, Molecular Biology and Biophysics, The University of Minnesota-Twin Cities, Minneapolis, Minnesota
19 shared publications - Hisham Abdelwahab
Department of Surgery, The University of Minnesota-Twin Cities, Minneapolis, Minnesota
19 shared publications - Joseph M. Muretta
University of Minnesota
19 shared publications
Latest Publications
- 6 November 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (11)
Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction
BACKGROUND: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multiomic evaluation of pulmonary artery banded pigs with differing degrees of right ventricular (RV) compromise. METHODS: Pulmonary artery banded pigs were stratified into mild and severe RVD groups based on RV ejection fraction (mild RVD, 38±4%; severe RVD, 20±8%). RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multiomic findings. RESULTS: Cardiac magnetic resonance imaging revealed progressive structural and functional alterations in mild and severe RVD pigs. Single-nucleus RNA sequencing demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, colocalization patterns in RV sections, and increased cardiomyocyte HIF1A (hypoxia-inducible factor 1 alpha) transcript expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared with severe RVD. Finally, integration of multiomic approaches identified activation of the ribotoxic stress response, impaired macrophage efferocytosis, and insufficient mitochondrial unfolded protein response as potential contributors to severe RVD. Multispecies comparison suggested that the ribotoxic stress response was the most conserved pathogenic response in RVD. CONCLUSIONS: Our multiomic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RVD. Future studies are needed to determine how engaging these pathways influences RV phenotypes.
- 6 November 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (11)
Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction
BACKGROUND: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multiomic evaluation of pulmonary artery banded pigs with differing degrees of right ventricular (RV) compromise. METHODS: Pulmonary artery banded pigs were stratified into mild and severe RVD groups based on RV ejection fraction (mild RVD, 38±4%; severe RVD, 20±8%). RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multiomic findings. RESULTS: Cardiac magnetic resonance imaging revealed progressive structural and functional alterations in mild and severe RVD pigs. Single-nucleus RNA sequencing demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, colocalization patterns in RV sections, and increased cardiomyocyte HIF1A (hypoxia-inducible factor 1 alpha) transcript expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared with severe RVD. Finally, integration of multiomic approaches identified activation of the ribotoxic stress response, impaired macrophage efferocytosis, and insufficient mitochondrial unfolded protein response as potential contributors to severe RVD. Multispecies comparison suggested that the ribotoxic stress response was the most conserved pathogenic response in RVD. CONCLUSIONS: Our multiomic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RVD. Future studies are needed to determine how engaging these pathways influences RV phenotypes.
- Open Access
Hepatocyte nuclear factor-1β recruits the nucleosome remodeling and deacetylase complex to activate gene transcription
Mutations affecting the transcription factor hepatocyte nuclear factor-1β (HNF-1β) are the most common monogenic cause of congenital anomalies of the kidney and urinary tract. The mechanism whereby HNF-1β regulates gene transcription remains unclear. Here, we performed an unbiased proteomic screen and found that endogenous HNF-1β interacts with core subunits of the nucleosome remodeling and deacetylase complex (NuRD) in renal epithelial cells. Genome-wide ChIP-seq studies demonstrated colocalization of endogenous HNF-1β and the core NuRD subunits GATAD2A, CHD4, and MBD3 at 2,776 primarily intergenic and intronic sites in native chromatin from wild-type renal epithelial cells. NuRD co-occupancy at 628 of the sites (22.6%) was reduced in the absence of HNF-1β. Of the 628 HNF-1β-dependent NuRD-occupied sites, 113 sites (18.2%) showed higher ATAC-seq peaks, indicative of open chromatin, and enrichment of histone H3 lysine-27 (H3K27) acetylation, indicative of active enhancers, in wild-type cells compared to HNF-1β-deficient cells. Correlation with transcriptomic profiles in wild-type and HNF-1β-deficient cells revealed that most of the sites were located near genes that are activated by HNF-1β. Knockdown of CHD4 with shRNA resulted in decreased expression of 67 HNF-1β-regulated genes that contained nearby NuRD and HNF-1β co-occupied sites. Collectively, these results demonstrate that HNF-1β recruits the NuRD complex resulting in H3K27 acetylation and chromatin opening and leading to gene activation. Our findings reveal a new mechanism of HNF-1β-dependent gene expression and expand the role of the NuRD complex in gene activation at distal enhancers.
Open AccessHepatocyte nuclear factor-1β recruits the nucleosome remodeling and deacetylase complex to activate gene transcription
Mutations affecting the transcription factor hepatocyte nuclear factor-1β (HNF-1β) are the most common monogenic cause of congenital anomalies of the kidney and urinary tract. The mechanism whereby HNF-1β regulates gene transcription remains unclear. Here, we performed an unbiased proteomic screen and found that endogenous HNF-1β interacts with core subunits of the nucleosome remodeling and deacetylase complex (NuRD) in renal epithelial cells. Genome-wide ChIP-seq studies demonstrated colocalization of endogenous HNF-1β and the core NuRD subunits GATAD2A, CHD4, and MBD3 at 2,776 primarily intergenic and intronic sites in native chromatin from wild-type renal epithelial cells. NuRD co-occupancy at 628 of the sites (22.6%) was reduced in the absence of HNF-1β. Of the 628 HNF-1β-dependent NuRD-occupied sites, 113 sites (18.2%) showed higher ATAC-seq peaks, indicative of open chromatin, and enrichment of histone H3 lysine-27 (H3K27) acetylation, indicative of active enhancers, in wild-type cells compared to HNF-1β-deficient cells. Correlation with transcriptomic profiles in wild-type and HNF-1β-deficient cells revealed that most of the sites were located near genes that are activated by HNF-1β. Knockdown of CHD4 with shRNA resulted in decreased expression of 67 HNF-1β-regulated genes that contained nearby NuRD and HNF-1β co-occupied sites. Collectively, these results demonstrate that HNF-1β recruits the NuRD complex resulting in H3K27 acetylation and chromatin opening and leading to gene activation. Our findings reveal a new mechanism of HNF-1β-dependent gene expression and expand the role of the NuRD complex in gene activation at distal enhancers.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1231-1251
GP130 Antagonism Enhances Porcine RV Function
BACKGROUND: Right ventricular (RV) dysfunction is a risk factor for death in multiple cardiovascular diseases, but RV-enhancing therapies are lacking. Inhibition of GP130 (glycoprotein-130) signaling with the small molecule SC144 improves RV function in rodent RV dysfunction via anti-inflammatory and metabolic mechanisms. However, SC144’s efficacy and molecular effects in a translational large animal model of RV dysfunction are unknown. METHODS: Four-week-old castrated male pigs underwent pulmonary artery banding (PAB). After 3 weeks, PAB pigs were randomized into 2 groups (daily injections of SC144 [2.2 mg/kg, PAB-SC144, n=5] or vehicle [PAB-Veh, n=5] for 3 weeks). Five age-matched pigs served as controls. Cardiac magnetic resonance imaging quantified RV size/function. Right heart catheterization evaluated hemodynamics. Single-nucleus RNA sequencing delineated cell-type-specific changes between experimental groups. Electron microscopy evaluated RV mitochondrial morphology. Phosphoproteomics identified dysregulated RV kinases. Lipidomics and metabolomics quantified lipid species and metabolites in RV tissue and serum. Quantitative proteomics examined RV mitochondrial protein regulation. Confocal microscopy evaluated alterations in cardiomyocyte size, macrophage abundances, capillary density, and pericyte/endothelial cell localization patterns. RESULTS: SC144 significantly improved RV ejection fraction (control: 60±4%; PAB-Veh: 22±10%; PAB-SC144: 37±6%) without altering RV afterload. Single-nucleus RNA sequencing demonstrated that PAB-Veh pigs had lower cardiomyocyte and higher macrophage/lymphocyte/pericyte/endothelial cell abundances as compared with control, and many of these changes were blunted by SC144. Immunohistochemistry validated the reduction in RV macrophage infiltration by SC144. Both transcriptomics and proteomics approaches demonstrated that SC144 combatted the downregulation of cardiomyocyte metabolic genes/proteins induced by PAB. Kinome enrichment analysis suggested SC144 counteracted RV mTORC1 (mammalian target of rapamycin complex 1) activation. Correspondingly, SC144 rebalanced the RV autophagy pathway proteins and improved mitochondrial morphology. Integrated lipidomics, metabolomics, and proteomics analyses revealed that SC144 restored fatty acid metabolism. Finally, CellChat analysis, cardiomyocyte RNAseq analysis, and histological examination suggested SC144 rebalanced pericyte-endothelial cell interactions and blunted cardiomyocyte HIF1 (hypoxia-induced factor 1) activation. CONCLUSIONS: GP130 antagonism blunts RV immune cell infiltration, reduces proinflammatory gene programs in macrophages and lymphocytes, rebalances autophagy, and preserves fatty acid metabolism in cardiomyocytes, and restores endothelial cell and pericyte homeostasis to mitigate cardiomyocyte hypoxia and ultimately augments RV function.
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1231-1251
GP130 Antagonism Enhances Porcine RV Function
BACKGROUND: Right ventricular (RV) dysfunction is a risk factor for death in multiple cardiovascular diseases, but RV-enhancing therapies are lacking. Inhibition of GP130 (glycoprotein-130) signaling with the small molecule SC144 improves RV function in rodent RV dysfunction via anti-inflammatory and metabolic mechanisms. However, SC144’s efficacy and molecular effects in a translational large animal model of RV dysfunction are unknown. METHODS: Four-week-old castrated male pigs underwent pulmonary artery banding (PAB). After 3 weeks, PAB pigs were randomized into 2 groups (daily injections of SC144 [2.2 mg/kg, PAB-SC144, n=5] or vehicle [PAB-Veh, n=5] for 3 weeks). Five age-matched pigs served as controls. Cardiac magnetic resonance imaging quantified RV size/function. Right heart catheterization evaluated hemodynamics. Single-nucleus RNA sequencing delineated cell-type-specific changes between experimental groups. Electron microscopy evaluated RV mitochondrial morphology. Phosphoproteomics identified dysregulated RV kinases. Lipidomics and metabolomics quantified lipid species and metabolites in RV tissue and serum. Quantitative proteomics examined RV mitochondrial protein regulation. Confocal microscopy evaluated alterations in cardiomyocyte size, macrophage abundances, capillary density, and pericyte/endothelial cell localization patterns. RESULTS: SC144 significantly improved RV ejection fraction (control: 60±4%; PAB-Veh: 22±10%; PAB-SC144: 37±6%) without altering RV afterload. Single-nucleus RNA sequencing demonstrated that PAB-Veh pigs had lower cardiomyocyte and higher macrophage/lymphocyte/pericyte/endothelial cell abundances as compared with control, and many of these changes were blunted by SC144. Immunohistochemistry validated the reduction in RV macrophage infiltration by SC144. Both transcriptomics and proteomics approaches demonstrated that SC144 combatted the downregulation of cardiomyocyte metabolic genes/proteins induced by PAB. Kinome enrichment analysis suggested SC144 counteracted RV mTORC1 (mammalian target of rapamycin complex 1) activation. Correspondingly, SC144 rebalanced the RV autophagy pathway proteins and improved mitochondrial morphology. Integrated lipidomics, metabolomics, and proteomics analyses revealed that SC144 restored fatty acid metabolism. Finally, CellChat analysis, cardiomyocyte RNAseq analysis, and histological examination suggested SC144 rebalanced pericyte-endothelial cell interactions and blunted cardiomyocyte HIF1 (hypoxia-induced factor 1) activation. CONCLUSIONS: GP130 antagonism blunts RV immune cell infiltration, reduces proinflammatory gene programs in macrophages and lymphocytes, rebalances autophagy, and preserves fatty acid metabolism in cardiomyocytes, and restores endothelial cell and pericyte homeostasis to mitigate cardiomyocyte hypoxia and ultimately augments RV function.
- Top Cited Papers
- 8 November 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1067-1083
Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension
BACKGROUND: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined. METHODS: Multiomics and physiological analyses evaluated how ferroptosis inhibition–modulated preclinical PAH. The impact of adeno-associated virus 1–mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension. RESULTS: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage–associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1- Acsl4 induced an inflammatory PAH phenotype in rats. Finally, single-nucleotide polymorphisms in 6 ferroptosis genes identified a potential link between ferroptosis and pulmonary hypertension severity in the Vanderbilt BioVU repository. CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.
- 8 November 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1067-1083
Top Cited PapersFerroptosis-Mediated Inflammation Promotes Pulmonary Hypertension
BACKGROUND: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined. METHODS: Multiomics and physiological analyses evaluated how ferroptosis inhibition–modulated preclinical PAH. The impact of adeno-associated virus 1–mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension. RESULTS: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage–associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1- Acsl4 induced an inflammatory PAH phenotype in rats. Finally, single-nucleotide polymorphisms in 6 ferroptosis genes identified a potential link between ferroptosis and pulmonary hypertension severity in the Vanderbilt BioVU repository. CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S1. DSC and DSG isoforms expressed in MCF-7 cells.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Desmoglein 2 Functions As A Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.